Immune checkpoint inhibitor-related myocarditis and meningoencephalitis induced by toripalimab - a case report and review of the literature

Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape of advanced lung cancer, particularly in patients with advanced or locally advanced non-small cell lung cancer. Toripalimab, a humanized anti-programmed cell death protein 1 (PD-1) monoclonal antibody, has demonstrated promising antitumor activity since its first official approval for the treatment of lung cancer in September 2022; however, like other ICIs, toripalimab may also induce immune-related adverse events (irAEs). Owing to its relatively short time on the market and the potential underreporting of some rare toxicities, the full safety profile of toripalimab has not yet been completely characterized. Reports of severe toripalimab-related myocarditis complicated by meningoencephalitis remain rare. By presenting this case and reviewing the relevant literature, this article aims to improve clinicians’ awareness of these potentially life-threatening immune-related toxicities and to facilitate their early recognition and timely management.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-20
DOI
https://doi.org/10.3389/fmed.2026.1977093
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune checkpoint inhibitor-related myocarditis and meningoencephalitis induced by toripalimab - a case report and review of the literature

Xinmiao Zhou, Zhuo Cao, Huamei Fan, Pan Ye
2 links
Frontiers in Medicine
Cancer Immunotherapy and Biomarkers
article

Immune checkpoint inhibitor-related myocarditis and meningoencephalitis induced by toripalimab - a case report and review of the literature

Xinmiao Zhou, Zhuo Cao, Huamei Fan, Pan Ye
article en

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape of advanced lung cancer, particularly in patients with advanced or locally advanced non-small cell lung cancer. Toripalimab, a humanized anti-programmed cell death protein 1 (PD-1) monoclonal antibody, has demonstrated promising antitumor activity since its first official approval for the treatment of lung cancer in September 2022; however, like other ICIs, toripalimab may also induce immune-related adverse events (irAEs). Owing to its relatively short time on the market and the potential underreporting of some rare toxicities, the full safety profile of toripalimab has not yet been completely characterized. Reports of severe toripalimab-related myocarditis complicated by meningoencephalitis remain rare. By presenting this case and reviewing the relevant literature, this article aims to improve clinicians’ awareness of these potentially life-threatening immune-related toxicities and to facilitate their early recognition and timely management.

Frontiers in MedicineVol. 13
Sir Run Run Shaw Hospital (CN), Zhejiang University (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon